China’s health insurance authority on Saturday released its 2026 catalog of medicines covered by national medical insurance, adding 107 drugs in the broadest single-year expansion yet of the treatments patients can claim at heavily negotiated prices. The update, issued jointly by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, takes effect on January 1, 2027.
Fifty-one of the newly included medicines are Class 1 innovative drugs, China’s designation for novel therapies developed domestically, a record for the program and the clearest sign yet that cost-control negotiators are prioritizing homegrown innovation alongside patient access. The additions concentrate on areas of unmet clinical need: oncology, rare diseases, chronic illness and psychiatric conditions, along with treatments for children and older patients with long-term conditions.
Several of the most expensive therapies ever to enter the scheme were among the headliners. A CAR-T cell therapy for lymphoma that previously cost patients more than one million yuan per treatment won a place on the reimbursed list, as did non-factor therapies for hemophilia. Entry into the catalog typically requires manufacturers to accept steep price cuts in exchange for access to the country’s hundreds of millions of insured patients.
The list is not only growing; it is also being pruned. Regulators removed 34 medicines judged to offer limited clinical value, to have superior alternatives available, or whose makers could not guarantee supply with complete documentation. After accounting for additions, removals and merged dosage forms, the catalog grew by a net 78 entries to 3,331 medicines, comprising 1,935 Western drugs and 1,396 traditional Chinese patent medicines, alongside 885 standardized herbal decoction pieces. Names of herbal pieces were realigned to the 2025 edition of the national pharmacopoeia.
Saturday’s announcement also updated the commercial health insurance innovative drug list, a parallel channel launched late last year for cutting-edge treatments too costly for the basic fund. Twelve drugs were added, bringing that list to 28, including the world’s first CAR-T therapy targeting solid tumors and China’s first gene therapy for hemophilia. Two products that debuted on the 2025 commercial list have now graduated into the basic medical insurance catalog, a linkage officials framed as a ladder from private coverage to universal reimbursement.
This is the ninth annual catalog adjustment since the healthcare security administration was established in 2018. Officials said negotiations were guided by pharmacoeconomic evaluation and fund-sustainability modeling, balancing lower out-of-pocket costs for patients against the long-term health of the insurance pool. Local authorities will now prepare hospital procurement and pharmacist training so the newly listed drugs are stocked and billable from the first day of 2027.

Dgcity